1988
DOI: 10.1200/jco.1988.6.4.689
|View full text |Cite
|
Sign up to set email alerts
|

A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.

Abstract: The interferons are a class of biological agents that have demonstrated antineoplastic activity in a variety of tumors both in vitro and in vivo. Previous reports have suggested that interferons can be safely administered by the intraperitoneal (IP) route with a pharmacokinetic advantage for peritoneal cavity exposure compared with the systemic circulation and with objective antitumor activity being demonstrated. On the basis of these reports and laboratory data suggesting activity for recombinant gamma-interf… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0
1

Year Published

1989
1989
1997
1997

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 50 publications
(14 citation statements)
references
References 14 publications
0
13
0
1
Order By: Relevance
“…Many investigations have been performed on the effects of IFN-y on tumor metastasis and invasion [9][10][11][12]. Moreover, clinical trials of intraperitoneal administration of IFN-), for malignant ascites have recently been reported by some investigators [13,14]. However, it remains unclear how IFN-y affects the interaction of tumor cells with peritoneal mesothelial cells, considered to be the initial step of peritoneal metastasis [1][2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…Many investigations have been performed on the effects of IFN-y on tumor metastasis and invasion [9][10][11][12]. Moreover, clinical trials of intraperitoneal administration of IFN-), for malignant ascites have recently been reported by some investigators [13,14]. However, it remains unclear how IFN-y affects the interaction of tumor cells with peritoneal mesothelial cells, considered to be the initial step of peritoneal metastasis [1][2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…It was effective in murine tumor systems when dosed locally for intraperitoneally implanted tumors [19]. Reportedly, rIFN-y did not show any antitumor effect in patients with ovarian cancer, but it was well tolerated with significant intraperitoneal levels being maintained beyond 24 hours [20]. Thus, in the present study to treat ovarian cancer we used the intraperitoneal route for rIFN-y administration.…”
Section: Discussionmentioning
confidence: 99%
“…Thus, in the present study to treat ovarian cancer we used the intraperitoneal route for rIFN-y administration. rIFN-7 has been reported to be highly safe at doses of 0.5 -2.0 x 106Iu/ma/weeks for as long as 24 weeks, although accompanied with varying degrees of some commonly reported side effects (overall incidence:54%) such as fever and flulike symptoms [20]. We selected a dose of 2 • 106IU rIFN-y/body, equivalent to 1.3 to 1.5 x 106IU/m 2, expecting good tolerance and sufficient efficacy.…”
Section: Discussionmentioning
confidence: 99%
“…In einer anderen Phase I-Studie wurde die intraperitonale Applikation von Interferon-g ohne antineoplastische Wirkung beschrieben [2].…”
Section: Interferonunclassified